首页 > 产品中心 > 试剂盒 > ADA检测试剂盒

Edrecolomab ELISA Kit (KPTX198)

概述
图片
参考文献

概述

货号	KPTX198
品牌	ProteoGenix
描述	Edrecolomab ELISA Kit (KPTX198) — Quantitative colorimetric ELISA. for Edrecolomab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Highlights High Sensitivity — Reliable quantification at low concentrations. Ready-to-Use — Pre-coated plates for streamlined workflow.
样本类型	Plasma, Serum
检测范围	0.31-5 μg/mL
保存溶液	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
检测方法	Colorimetric
实验类型	Quantitative
回收率	80-120%
运输	2-8 ℃
规格	Edrecolomab
别名	17-1A, CAS: 156586-89-9
背景	Edrecolomab, also known as MAb17-1A, is a mouse-derived IgG2a monoclonal antibody targeted at the cell-surface glycoprotein EpCAM (17-1A). This drug was developed by Centocor in an attempt to prevent colorectal cancer and adenocarcinoma. Edrecolomab has been investigated in the clinical trials for the treatment of colon cancer. Edrecolomab was licensed as an adjuvant therapy for postoperative colorectal cancer by German authorities with the trade name Panorex in 1995. However, in 2004, researchers applied edrecolomab to the study of postoperative adjuvant therapy in patients with colorectal cancer. The results showed that edrecolomab adjuvant therapy can help Dukes'CCRC patients to restore the lack of immune response in the body, but the randomized trials of clinical efficacy were unsatisfactory. Then in 2005, Edrecolomab was studied in a phase 3 randomized trial of postoperative adjuvant therapy for colorectal cancer. However, the results showed that Edrecolomab did not improve overall survival or disease-free survival in patients with stage II colon cancer treated with postoperative adjuvant therapy. Subsequently, Edrecolomab in combination with fluorouracil (FU) was used to treat colorectal cancer in the III stage. However, the results showed that the addition of ED in the basic treatment of fluorouracil had no significant effect on OS. Edrecolomab also did not prolong patient survival in subsequent randomized trials. Although Edrecolomab has not shown very good results in previous studies of colorectal cancer, it is still a promising monoclonal antibody for the treatment of adenocarcinomas expressing EpCAM.
Note	For Research Use Only.

图片

参考文献

公式

质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)

填写 质量、浓度、体积中的任意 2 项 + 分子量，自动计算未知值。

质量

=

浓度

×

体积

分子量 *

g/mol

公式

C₁ × V₁ = C₂ × V₂

填写 4 项中的任意 3 项，自动计算未知值。

母液

C₁ (起始浓度)

×

V₁ (起始体积)

=

工作液

C₂ (终浓度)

×

V₂ (终体积)

相关产品推荐

Edrecolomab ELISA Kit

7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东

24小时产品查询
扫一扫关注我们
专属渠道经理

Copyright © 2026 武汉艾必赛生物科技有限公司版权所有所有产品仅可用于工业或者科研等非医疗目的。

鄂ICP备2023002448号-2